ADC Therapeutics Archives -

ADC Therapeutics has said it will not seek accelerated approval of its Hodgkin lymphoma drug camidanlumab tesirine (cami)

FDA blocks early filing for ADC drug, signalling tougher stance

https://pharmaphorum.com/news/fda-blocks-early-filing-for-adc-drug-signalling-tougher-stance/

In this new segment from pharmaphorum, we collect the most significant hirings, firings, and recruitment stories from across

The ins and outs of the life sciences: top hires for October 2022

https://pharmaphorum.com/news/the-ins-and-outs-of-the-life-sciences-top-hires-for-october-2022/

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy

Sobi bolsters blood division via $435m ADC licensing deal

https://pharmaphorum.com/news/sobi-bolsters-blood-division-via-435m-adc-licensing-deal/

ADC Therapeutics is looking to add a second approved antibody-drug conjugate to its portfolio after reporting strong phase

EHA: ADC preps filings for Hodgkin lymphoma drug after ph2 readout

https://pharmaphorum.com/news/eha-adc-preps-filings-for-hodgkin-lymphoma-drug-after-ph2-readout/

ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a

FDA sets May date for verdict on ADC’s lymphoma drug Lonca

https://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/

Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop

ADC Therapeutics sets terms for $125m IPO

https://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/

ADC Therapeutics